ATE231504T1 - Pyrazolderivate und sie enthaltende cox- inhibitoren - Google Patents

Pyrazolderivate und sie enthaltende cox- inhibitoren

Info

Publication number
ATE231504T1
ATE231504T1 AT98912761T AT98912761T ATE231504T1 AT E231504 T1 ATE231504 T1 AT E231504T1 AT 98912761 T AT98912761 T AT 98912761T AT 98912761 T AT98912761 T AT 98912761T AT E231504 T1 ATE231504 T1 AT E231504T1
Authority
AT
Austria
Prior art keywords
compounds
cox
lower alkyl
halogeno
disturbances
Prior art date
Application number
AT98912761T
Other languages
English (en)
Inventor
Tomoji Aotsuka
Nagatoshi Wagatsuma
Hideo Kato
Naoki Ashizawa
Original Assignee
Grelan Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Grelan Pharmaceutical Co filed Critical Grelan Pharmaceutical Co
Application granted granted Critical
Publication of ATE231504T1 publication Critical patent/ATE231504T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT98912761T 1997-04-11 1998-04-10 Pyrazolderivate und sie enthaltende cox- inhibitoren ATE231504T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP10829997 1997-04-11
PCT/JP1998/001664 WO1998046594A1 (en) 1997-04-11 1998-04-10 Pyrazole derivatives and cox inhibitors containing them

Publications (1)

Publication Number Publication Date
ATE231504T1 true ATE231504T1 (de) 2003-02-15

Family

ID=14481176

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98912761T ATE231504T1 (de) 1997-04-11 1998-04-10 Pyrazolderivate und sie enthaltende cox- inhibitoren

Country Status (6)

Country Link
US (1) US6136831A (de)
EP (1) EP1006114B1 (de)
JP (1) JP4357004B2 (de)
AT (1) ATE231504T1 (de)
DE (1) DE69810938T2 (de)
WO (1) WO1998046594A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6403640B1 (en) 1999-08-27 2002-06-11 Merck & Co., Inc. Method for treating chronic prostatitis or chronic pelvic pain syndrome
US6897208B2 (en) 2001-10-26 2005-05-24 Aventis Pharmaceuticals Inc. Benzimidazoles
FR2831537B1 (fr) * 2001-10-26 2008-02-29 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation
FR2831536A1 (fr) * 2001-10-26 2003-05-02 Aventis Pharma Sa Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr
MXPA04003954A (es) * 2001-10-26 2004-11-29 Aventis Pharma Inc Bencimidazoles.
EP1442028A4 (de) * 2001-11-06 2009-11-04 Bristol Myers Squibb Co Substituierte säurederivate, die sich als antidiabetika und mittel gegen obesitas eignen, und verfahren
US6861533B2 (en) 2001-11-23 2005-03-01 Irm Llc Solution phase sythesis of arylbenzoxazoles
US20030220374A1 (en) * 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
US20030212138A1 (en) * 2002-01-14 2003-11-13 Pharmacia Corporation Combinations of peroxisome proliferator-activated receptor-alpha agonists and cyclooxygenase-2 selective inhibitors and therapeutic uses therefor
WO2004002420A2 (en) 2002-06-28 2004-01-08 Nitromed, Inc. Oxime and/or hydrazone containing nitrosated and/or nitrosylated cyclooxigenase-2 selective inhibitors, compositions and methods of use
US7847101B2 (en) 2002-07-24 2010-12-07 Valocor Therapeutics, Inc. Pyrazolylbenzothiazole derivatives and their use as therapeutic agents
US20040147581A1 (en) * 2002-11-18 2004-07-29 Pharmacia Corporation Method of using a Cox-2 inhibitor and a 5-HT1A receptor modulator as a combination therapy
ES2341240T3 (es) 2002-12-13 2010-06-17 Warner-Lambert Company Llc Ligando alfa-2-delta para tratar los sintomas del tracto urinario inferior.
US20040220155A1 (en) * 2003-03-28 2004-11-04 Pharmacia Corporation Method of providing a steroid-sparing benefit with a cyclooxygenase-2 inhibitor and compositions therewith
ATE342722T1 (de) 2003-05-07 2006-11-15 Osteologix As Behandlung von knorpel/knochen-erkrankungen mit wasserlöslichen strontiumsalzen
DK1622630T3 (da) 2003-05-07 2012-12-17 Osteologix As P009368epdk1
WO2005009342A2 (en) * 2003-07-16 2005-02-03 Pharmacia Corporation Method for the treatment or prevention of dermatological disorders with a cyclooxygenase-2 inhibitor alone and in combination with a dermatological treatment agent and compositions therewith
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
WO2005023189A2 (en) * 2003-09-03 2005-03-17 Pharmacia Corporation Method of cox-2 selective inhibitor and nitric oxide-donating agent
EP1708718A1 (de) 2004-01-22 2006-10-11 Pfizer Limited Triazol-derivate zur hemmung der vasopressing-antagonistischen aktivität
CA2563963A1 (en) * 2004-04-28 2005-11-10 Pfizer Inc. 3-heterocyclyl-4-phenyl-triazole derivatives as inhibitors of the vasopressin v1a receptor
WO2008047694A1 (fr) * 2006-10-13 2008-04-24 Aska Pharmaceutical Co., Ltd. Procédé de fabrication d'un composé benzothiazole
UA94979C2 (uk) 2006-12-22 2011-06-25 Рекордати Айеленд Лимитед КОМБІНОВАНА ТЕРАПІЯ ПОРУШЕНЬ НИЖНІХ СЕЧОВИВІДНИХ ШЛЯХІВ ЛІГАНДАМИ α2δ І НПЗП
US11583516B2 (en) 2016-09-07 2023-02-21 Trustees Of Tufts College Dash inhibitors, and uses related thereto
GB201617339D0 (en) 2016-10-12 2016-11-23 Lytix Biopharma As Therapeutic compounds
US20240165148A1 (en) 2021-03-15 2024-05-23 Saul Yedgar Hyaluronic acid-conjugated dipalmitoyl phosphatidyl ethanolamine in combination with non-steroidal anti-inflammatory drugs (nsaids) for treating or alleviating inflammatory diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1143365A (zh) * 1994-01-10 1997-02-19 麦克弗罗斯特(加拿大)有限公司 作为cox-2抑制剂的苯基杂环类化合物
JP2636819B2 (ja) * 1994-12-20 1997-07-30 日本たばこ産業株式会社 オキサゾール系複素環式芳香族化合物
JP3181190B2 (ja) * 1994-12-20 2001-07-03 日本たばこ産業株式会社 オキサゾール誘導体
US5700816A (en) * 1995-06-12 1997-12-23 Isakson; Peter C. Treatment of inflammation and inflammation-related disorders with a combination of a cyclooxygenase-2 inhibitor and a leukotriene A4 hydrolase inhibitor

Also Published As

Publication number Publication date
EP1006114A1 (de) 2000-06-07
DE69810938T2 (de) 2003-11-06
WO1998046594A1 (en) 1998-10-22
EP1006114A4 (de) 2000-06-07
US6136831A (en) 2000-10-24
JP4357004B2 (ja) 2009-11-04
EP1006114B1 (de) 2003-01-22
DE69810938D1 (de) 2003-02-27

Similar Documents

Publication Publication Date Title
ATE231504T1 (de) Pyrazolderivate und sie enthaltende cox- inhibitoren
NO953305D0 (no) Antranilsyrederivat
NO20013379L (no) 4-okso-1,4-dihydro-3-kinolinkarboksamider som antivirusmidler
BR9807872A (pt) AtropisÈmeros de 3-aril-4(3h)-quinazolinonas e seu uso como antagonistas de receptor ampa
DE69838172D1 (de) Oxindolylchinazolinderivate als angiogenesehemmer
DK0634401T3 (da) MDR-reverserende midler
NO20015669L (no) Heterocykliske substituerte aminoazacykler nyttige som sentralnervesystemmidler
DK0887344T3 (da) Quinoliner og quinazoliner, som er nyttige ved terapi
DE69717970D1 (de) Chinolin carbonsaure-derivate und ihre salze
DK0514277T3 (da) 3-aminopyradazinderivater med virkning på centralnervesystemet
DK0425209T3 (da) Naphtyloxazolidon Derivater
TR200001950T2 (tr) İkameli 2-benzilamino-2-fenil-asetamid bileşikler.
MX2007000016A (es) Derivados de pirazol.
BR9801506A (pt) Compostos de quinolina e quinazolina úteis em terapia.
ATE327979T1 (de) Pyrazolinon-derivate
DK0480155T3 (da) 4-Substituerede dihydropyrido(4,3-d)pyrimidiner som analgetica og topiske antiinflammatoriske midler til behandling af hudlidelser
ATE247660T1 (de) Furopyridinderivate und ihre therapeutische verwendung
WO1998051667A1 (en) Indole derivatives and mono- and diazaindole derivatives
EP1319658A4 (de) Imidazolderivate oder ihre salze
MX9709955A (es) Derivados del acido 5-pirazolilbenzoico.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties